Wang Q, Wan Q, Li T, Wang X, Hu Y, Zhong Z
Arch Gynecol Obstet. 2023; 309(2):679-688.
PMID: 38032411
DOI: 10.1007/s00404-023-07285-1.
He Y, Tang Y, Chen S, Liu J, Liu H
BMC Pregnancy Childbirth. 2022; 22(1):172.
PMID: 35236312
PMC: 8892730.
DOI: 10.1186/s12884-022-04499-0.
Deepika K, Suvarna R, Sumi M, Snehal D, Arveen V, Anuja K
JBRA Assist Reprod. 2020; 25(1):48-58.
PMID: 32960521
PMC: 7863104.
DOI: 10.5935/1518-0557.20200028.
Ezoe K, Murata N, Yabuuchi A, Kobayashi T, Kato K
Sci Rep. 2019; 9(1):12519.
PMID: 31467307
PMC: 6715633.
DOI: 10.1038/s41598-019-48918-3.
Aflatoonian A, Mansoori-Torshizi M, Farid Mojtahedi M, Aflatoonian B, Khalili M, Amir-Arjmand M
Int J Reprod Biomed. 2018; 16(1):9-18.
PMID: 29675483
PMC: 5899765.
Repeat Dose of Gonadotropin-releasing Hormone Agonist Trigger in Polycystic Ovarian Syndrome Undergoing Fertilization Cycles Provides a Better Cycle Outcome - A proof-of-concept Study.
Deepika K, Baiju P, Gautham P, Suvarna R, Arveen V, Kamini R
J Hum Reprod Sci. 2018; 10(4):271-280.
PMID: 29430154
PMC: 5799931.
DOI: 10.4103/jhrs.JHRS_102_17.
Plasmatic estradiol concentration in the mid-luteal phase is a good prognostic factor for clinical and ongoing pregnancies, during stimulated cycles of in vitro fertilization.
Florencio R, Meira M, Cunha M, Camarco M, Castro E, Finotti M
JBRA Assist Reprod. 2018; 22(1):8-14.
PMID: 29338136
PMC: 5844653.
DOI: 10.5935/1518-0557.20180005.
Gonadotropin-releasing hormone agonist trigger is a better alternative than human chorionic gonadotropin in PCOS undergoing IVF cycles for an OHSS Free Clinic: A Randomized control trial.
Krishna D, Dhoble S, Praneesh G, Rathore S, Upadhaya A, Rao K
J Hum Reprod Sci. 2016; 9(3):164-172.
PMID: 27803584
PMC: 5070398.
DOI: 10.4103/0974-1208.192056.
GnRH agonist trigger versus hCG trigger in GnRH antagonist in IVF/ICSI cycles: A review article.
Alyasin A, Mehdinejadiani S, Ghasemi M
Int J Reprod Biomed. 2016; 14(9):557-566.
PMID: 27738657
PMC: 5054292.
GnRH agonist with low-dose hCG (dual trigger) is associated with higher risk of severe ovarian hyperstimulation syndrome compared to GnRH agonist alone.
ONeill K, Senapati S, Maina I, Gracia C, Dokras A
J Assist Reprod Genet. 2016; 33(9):1175-84.
PMID: 27349252
PMC: 5010813.
DOI: 10.1007/s10815-016-0755-8.
Comparison of hCG triggering versus hCG in combination with a GnRH agonist: a prospective randomized controlled trial.
Decleer W, Osmanagaoglu K, Seynhave B, Kolibianakis S, Tarlatzis B, Devroey P
Facts Views Vis Obgyn. 2015; 6(4):203-9.
PMID: 25593695
PMC: 4286859.
Use of gonadotropin-releasing hormone agonist trigger during in vitro fertilization is associated with similar endocrine profiles and oocyte measures in women with and without polycystic ovary syndrome.
ONeill K, Senapati S, Dokras A
Fertil Steril. 2014; 103(1):264-9.
PMID: 25450300
PMC: 4866644.
DOI: 10.1016/j.fertnstert.2014.09.042.
Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology.
Youssef M, van der Veen F, Al-Inany H, Mochtar M, Griesinger G, Mohesen M
Cochrane Database Syst Rev. 2014; (10):CD008046.
PMID: 25358904
PMC: 10767297.
DOI: 10.1002/14651858.CD008046.pub4.
Social oocyte freezing.
Stoop D
Facts Views Vis Obgyn. 2014; 2(1):31-4.
PMID: 25206964
PMC: 4154335.
Persistent ascites resolving with gonadotropin-releasing-hormone-agonist 18 months after hospitalization for severe ovarian hyperstimulation syndrome.
Comba C, Ugurlucan F, Bastu E, Iyibozkurt A, Topuz S
Arch Gynecol Obstet. 2013; 289(1):223-5.
PMID: 23846619
PMC: 3889824.
DOI: 10.1007/s00404-013-2940-7.
GnRH analogues in the prevention of ovarian hyperstimulation syndrome.
Alama P, Bellver J, Vidal C, Giles J
Int J Endocrinol Metab. 2013; 11(2):107-16.
PMID: 23825982
PMC: 3693668.
DOI: 10.5812/ijem.5034.